<DOC>
	<DOCNO>NCT01491815</DOCNO>
	<brief_summary>This international ( Nordic ) trial design compare safety efficacy active conventional therapy ( ACT ) three biologic treatment subject early rheumatoid arthritis ( RA ) . The global aim study ass compare 1. proportion subject achieve remission ACT versus three different biologic therapy ( Certolizumab-pegol , Abatacept Tocilizumab ) 2. two alternative de-escalation strategy patient respond first-line therapy .</brief_summary>
	<brief_title>Active Conventional Therapy Compared Three Different Biologic Treatments Early Rheumatoid Arthritis With Subsequent Dose Reduction</brief_title>
	<detailed_description>There currently 296 patient include 73 enter treatment part 2 . 32 patient exit study treatment part 1 , 45 patient early termination , five patient complete full study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Subject ≥18 year age . 2 . Subject diagnosis RA define newly establish ACR/EULAR criterion , 2010 . ( Patients also classify accord 1987revised ACRclassification criterion , without inclusion criterion ) . 3 . &lt; 24 month arthritis symptom debut ( symptom duration register ) . 4 . Subject must DAS28 ( CRP ) &gt; 3.2 . 5 . ≥ 2 swollen joint AND ≥ 2 tender joint . 6 . Subject must fulfill one follow three criterion : RF positive OR ACPA positive OR CRP &gt; 10 mg/L . 7 . Female subject either childbearing potential ( postmenopausal , surgically sterile etc . ) , childbearing potential practice one follow method birth control throughout study 150 day study completion : Intrauterine device ( IUD ) Contraceptives ( oral , parenteral , patch ) three month prior study drug administration ) A vasectomized partner 8 . Female subject childbearing potential must negative serum pregnancy test Screening visit . 9 . Subject judge good general health determine principal investigator base upon result medical history , laboratory profile , physical examination , chest Xray ( CXR ) , 12lead electrocardiogram ( ECG ) perform Screening . 10 . Subjects must able willing provide write informed consent comply requirement study protocol . 11 . Subjects must able willing selfadminister s.c. injection qualify person available administer s.c. injection . 1 . Subject previously treat disease modify antirheumatic drug ( DMARDs ) rheumatic disease . 2 . Current active inflammatory joint disease RA . 3 . Subjects dose prednisone ( equivalent ) &gt; 7.5 mg/day dose change within precede 4 week . 4 . Subject treat intraarticular parenteral administration corticosteroid precede 4 week . Inhaled corticosteroid stable medical condition allow . 5 . Subject undergone joint surgery within precede two month ( joint assess within study ) . 6 . Subject chronic arthritis diagnose age 17 year . 7 . Subject history allergic reaction significant sensitivity constituent study drug . 8 . Subject treated investigational drug within one month prior screen visit . 9 . Active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization within 4 week screen . 10 . Subject poorly control medical condition , uncontrolled diabetes , unstable heart disease , congestive heart failure , recent cerebrovascular accident condition , opinion investigator , would put subject risk participation study . 11 . Subject history clinically significant hematologic ( e.g. , severe anemia , leukopenia , thrombocytopenia ) , renal liver disease ( e.g. , fibrosis , cirrhosis , hepatitis ) . 12 . Subject history neurologic symptom suggestive central nervous system ( CNS ) demyelinate disease and/or diagnosis central demyelinate disease . 13 . Subject history cancer lymphoproliferative disease . Allowable exception : 1 . Successfully treat cutaneous squamous cell basal cell carcinoma 2 . Localized carcinoma situ cervix 3 . Curatively treated malignancy ( treatment terminate ) &gt; 5 year prior screen 14 . Subject history listeriosis , histoplasmosis , untreated TB , persistent chronic infection , recent active infection require hospitalization treatment intravenous ( iv ) antiinfectives within 30 day oral antiinfectives within 14 day prior BL visit . 15 . Subjects evaluate latent TB infection PPD QuantiFERON test Xray . Subjects evidence latent TB enrol first assess accord local guideline . 16 . Subject know immune deficiency , history Human Immunodeficiency Virus ( HIV ) otherwise severely immunocompromised . 17 . Female subject pregnant breastfeeding consider become pregnant study within 150 day last dose study medication . 18 . Men plan father child time include study 19 . Subject history clinically significant drug alcohol usage last year . 20 . Subject chronic widespread pain syndrome . 21 . Subject consider investigator , reason , unsuitable candidate study . 22 . Subject unwilling comply study protocol . 23 . Screening clinical laboratory analyse show follow abnormal laboratory result : 1 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 1.75 time upper limit normal ( ULN ) . 2 . Positive serum human chorionic gonadotropin ( hCG ) . 3 . Positive test hepatitis B surface antigen ( HBsAg ) hepatitis C serology indicative current infection . 4 . Creatinine level &gt; 2x ULN . If creatinine 12 time ULN , check GFR . 5 . Hemoglobin &lt; 90 g/L . 6 . Absolute neutrophil count ( ANC ) &lt; 1.5 x 10^3/microL . 7 . Serum total bilirubin &gt; 1.5 mg/dL ( &gt; 26 micromol/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>